Tyra Biosciences reports Q2 EPS (32c), consensus (41c)

Reports Q2 revenue $0, consensus $0. As of June 30 TYRA had cash, cash equivalents, and marketable securities of $373.8M. The Company’s current cash, cash equivalents and marketable securities are expected to allow TYRA to execute on its plans through at least 2026. “This is an exciting time at TYRA. With the recent clearance of our IND for TYRA-430, our FGFR4/3 biased inhibitor, we are well positioned with three potentially best-in-class precision molecules in the clinic for oncology. In skeletal dysplasias, we made great progress with preclinical proof-of-concept data in hypochondroplasia and continued execution towards the filing of our IND anticipated in the second half of 2024 to support our planned Phase 2 study in achondroplasia,” said Todd Harris, CEO of TYRA.